Over 600 Thai medical workers infected despite taking two China-made Covid vaccine Sinovac

NewsBharati    13-Jul-2021
Total Views |
Bangkok, July 13: Thailand health ministry said that more than 600 medical workers who received two doses of China's Sinovac vaccine have been infected with Covid-19. According to the reports, a nurse has passed away due to these vaccines while a medical worker is in critical condition.
 
vaccine_1  H x
 
In a news briefing, senior health official, Sopon Iamsirithawon, said that from the month of April 2021 to July 2021, 677,348 medical personnel had been jabbed with the Chinese vaccines, out of which, more than 600 have been infected with Covid-19. An expert panel, now, has recommended a third dose to trigger immunity for medical workers who are at risk of getting infected.
 
Also Read: 'Chinese actions led to India-China border tension', MEA hits back
 
"This will be a different vaccine, either viral vector AstraZeneca or an mRNA vaccine, which Thailand will be receiving in the near term," Sopon Iamsirithawon said, adding that the recommendation will be considered on Monday. The announcement comes at a time when Thailand has reported a total of 336,371 confirmed infections and 2,711 Covid related deaths since the pandemic began last year.
 
 
It should be noted that Singapore is excluding people who received Sinovac Biotech (SVA.O) vaccine shots from the country’s total count of vaccinations against COVID-19. The country’s health ministry suggested that this was done citing “inadequate efficacy data for the Chinese-made vaccine, especially against the contagious Delta variant.”
 
Also Read: Absurd? China advises 'border issue should not be linked to bilateral relations'
 
Health Minister Ong Ye Kung in a media briefing on July 7, said, "We don't really have a medical or scientific basis or have the data now to establish how effective Sinovac is in terms of infection and severe illnesses on Delta." Both (Moderna Inc. & Pfizer Inc.) have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with trials for Sinovac that showed results from as low as 51% to about 84%.